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Abstract
Introduction: Antibodies reacting with various microbial epitopes have been described in inflammatory bowel disease (IBD) 
and are associated with a specific diagnosis and clinical presentation. 
Aim: To evaluate the profile of new anti-glycan antibodies, their potential association with disease phenotype and diagnostic 
accuracy in paediatric Crohn’s disease (CD).
Material and methods: Blood samples from 134 paediatric IBD patients (109 CD, 25 ulcerative colitis (UC)) and 67 controls 
were blindly analysed for anti-Saccharomyces cerevisiae (ASCA), anti-chitobioside carbohydrate (ACCA), anti-laminaribioside car-
bohydrate (ALCA), and anti-mannobioside carbohydrate (AMCA) antibodies using commercially available assays. The serological 
response to glycans was correlated with clinical disease characteristics. 
Results: At least one of the tested anti-glycan antibodies was present in 75% of CD patients. Despite the high frequency 
of reactivity to glycan epitopes, a limited overlap of serological markers was observed. In total, 49% of ASCA-negative patients 
presented with one of the following: ACCA, ALCA, or AMCA. The occurrence of one antibody from the anti-glycan panel was inde-
pendently associated with complicated disease phenotype and ileocolonic disease location. A higher level of immune response 
as assessed by the quartile sum scores for ACCA, ALCA, and AMCA was linked with older age at diagnosis (10–17 years) and 
ileocolonic disease location. The ASCA had the greatest accuracy for diagnosis and differentiation of CD. 
Conclusions: Qualitative and quantitative serologicalal response to glycan epitopes was associated with distinct clinical 
presentation in paediatric CD patients. This raises the possibility for the use of these markers to differentiate subgroups of CD 
patients with more sever clinical presentation. The ASCA was the most accurate serological marker for CD; however, testing for 
the new anti-glycan antibodies may constitute an adjunctive tool in a specific group of patients to aid in the differentiation of 
CD with absent ASCA from ulcerative colitis.
Introduction
Crohn’s disease (CD) and ulcerative colitis (UC), the 
two major subtypes of inflammatory bowel disease 
(IBD), represent heterogeneous groups of chronic, sys-
temic inflammatory disorders, mainly affecting the gas-
trointestinal tract. Although the exact aetiology still re-
mains a subject of debate, there is clear evidence that 
an aberrant immune response to intestinal microbiome 
components affected by environmental factors plays 
a role in genetically predisposed individuals [1, 2]. Both 
UC and CD present with a wide range of pathogenetic 
pathways that have diverse and often nonspecific clinical 
presentations, a variable course, and an unpredictable 
response to treatment [3–6]. Establishing the diagnosis 
and differentiation of CD and UC is a complex and some-
times challenging process, based on a combination of 
clinical, laboratory, imaging, endoscopic, and pathologi-
cal criteria [7, 8]. Despite impressive progress in the eval-
uation tools, in some patients the diagnosis is delayed 
or missed, and a subset of patients with isolated colitis 
remains unclassified. In the data recently published by 
de Bie et al. on the European paediatric IBD registry, 9% 
of 2087 newly diagnosed patients were identified with 
an unclassified type of the disease (IBD-U) [5]. 
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Aberrations in immune response are well known to 
be present in IBD, and antibodies directed against a va-
riety of microbial and self antigens have been proposed 
as useful tools in differentiating patients with IBD from 
non-IBD individuals, and in distinguishing the subtypes 
of IBD [9–11]. The first described and yet the most exten-
sively studied CD-associated serological marker directed 
to mannose epitopes of the cell wall of the yeast Sac-
charomyces cerevisiae (ASCA) is present in 29–69% of CD 
patients, 0–29% of UC subjects, and 0–16% of healthy 
controls [9, 10, 12]. For UC, DNase-sensitive “atypical” 
antibodies directed to perinuclear components of neu-
trophils (pANCA), present in 41–73% of UC, 6–38% of 
CD subjects, and 0–8% of controls, remain a recognis-
able serological marker [9, 10]. The results presented by 
numerous studies indicate that both ASCA and pANCA 
individually have only modest accuracy in detecting and 
differentiating inflammatory bowel disease, and con-
cerns about the sensitivity of the reported wide range 
extending from 37% to 72% limit their usability as 
a screening tool [7, 13]. After pANCA and ASCA, many ad-
ditional types of antibodies have been described as be-
ing linked with CD, including those against Pseudomonas 
fluorescens-associated sequence I2 (Anti-I2), outer mem-
brane porin C (OmpC) of Escherichia coli, and bacterial 
flagellin cBir1 (Anti-CBir1) [10, 14]. The correlation of the 
presence (qualitative) and level of serological (quantita-
tive) response to those various protein and carbohydrate 
antigens with the disease phenotype, disease severity, 
and the course of disease and disease-related surgery 
requirements, have been reported for CD patients [9, 10, 
15–18]. More recently, the presence of members of the 
anti-glycan antibodies family other than ASCA, including 
anti-mannobioside carbohydrate IgA antibodies (AMCA), 
anti-laminaribioside carbohydrate IgA antibodies (ALCA), 
and anti-chitobioside carbohydrate IgG antibodies 
(ACCA), has been recognised as being associated with 
CD in adults, but limited data are available with respect 
to paediatric patients [19–22].
In the era of personalised medicine, identification of 
patients with complicated disease and a poor progno-
sis is becoming a challenging issue, with special impor-
tance attached to decision-making strategy to optimise 
the therapy for individual patients. 
Aim
Therefore, it has been our objective in the present 
study to assess the profile of serological response to 
the panel of glycan epitopes (ASCA, ACCA, ALCA, and 
AMCA) and to evaluate a new set of anti-glycan anti-
bodies, their diagnostic and differential usefulness, and 
their potential association with disease phenotype in 
paediatric-onset CD patients. 
Material and methods
Patient population
Blood samples were obtained from 109 CD patients 
and 25 UC patients, who were referred for investigation 
to our tertiary-care referral centre. As the controls, we re-
cruited 67 children (34 boys, 33 girls, mean age (± SD) 
10.63 ±4.56 years) diagnosed with acute diseases (acute 
gastroenteritis, acute ear, nose, or throat disorders). The 
exclusion criteria for the controls included the following: 
suspicion of inflammatory bowel disorders, gastrointesti-
nal bleeding, presence of any chronic diseases, and posi-
tive family history for immunological and gastrointestinal 
disorders. Diagnosis and differentiation of CD and UC 
were performed based on clinical, endoscopic, histolog-
ical, and imaging investigations according to the Porto 
criteria [7]. The phenotype of the disease was assigned 
using the Paris classification [8]. Clinical and demograph-
ic characteristics of the IBD patients are presented in 
Table I. Informed consent was obtained from all parents/
legal guardians and from patients above 16 years of age. 
The study was approved by the Institutional Research Eth-
ics Board at the Jagiellonian University Medical College. 
Serological analysis
All blood samples were drawn at the time of the 
enrolment, and further analysis was performed in a ran-
dom and blind fashion. To detect ACCA IgA, ALCA IgG, 
and AMCA the IgG sera were immediately separated by 
centrifugation and stored at –20°C until analysis, which 
was performed with commercially available, specific en-
zyme-immunosorbent assay (ELISA) kits (Glycominds 
LTD, Lod, Israel) according to the manufacturer’s proto-
col (Glycominds LTD, Lod, Israel). The results were pre-
sented as arbitrary ELISA units (EU), which were calcu-
lated based on the sample and calibrator optical density 
and documented both in absolute values and frequency 
of positivity. The cut-off values for positive tests were 
assessed according to the manufacturer’s recommen-
dations as follows: 90 EU/ml, 60 EU/ml, and 100 EU/ml 
for ACCA, ALCA, and AMCA, respectively. In addition to 
the qualitative analysis, to evaluate the level of immune 
response of ACCA, ALCA, and AMCA and possible asso-
ciation with distinct CD phenotypes, quartile scores for 
each of these serologicalal markers were calculated. In 
brief, for each antigen, the patients whose antibody lev-
els were in the first, second, third, and fourth quartile of 
the distribution were assigned a quartile score of 1, 2, 3, 
and 4, respectively. By adding individual quartile scores 
for each of the glycan antigens a quartile sum score 
(range Q3–Q12) representing the cumulative immune 
response toward all the three new anti-glycan antigens 
for each individual patient was calculated. 
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Determination of ASCA IgA and IgG was performed 
by the indirect immunofluorescence technique using 
a commercially available kit according to the manu-
facturer’s instructions (EUROIMMUN, Germany). The 
cut-off values for positivity were set at 1/100 for IgG 
and 1/1000 for IgA, as recommended by the manufac-
turer (EUROIMMUN, Germany). Diagnostic parameters 
(sensitivity, specificity, positive and negative predictive 
values) were calculated individually for each of the se-
rological markers. To determinate the accuracy of ACCA, 
ALCA, and AMCA in differentiation between CD, UC, and 
the controls independently of the cut-off values, receiv-
er operating characteristic (ROC) curves were generated 
by plotting sensitivity versus 1-specificity.
Statistical analysis
Data were analysed using StatSoft Statistica soft-
ware system version 10. All the quantitative variables 
were presented as means ± standard deviations (SD) 
for symmetrically distributed data, or as median inter-
quartile range (INQ) for skewed data. All categorical 
variables were presented as numbers of patients and 
percentages. Unpaired categorical data were compared 
using the χ2 or Fischer’s exact test, as appropriate. The 
unpaired t-test, Wilcoxon’s rank-sum test, or Kruskal – 
Wallis test were used to compare continuous variables, 
as appropriate for the data normality and number of 
contrasting groups. The Mann-Whitney test was used 
for comparison of medians. Multivariate logistic regres-
sion analysis was performed to define independent pre-
dictors of seropositivity for each individual marker and 
age at diagnosis, location, and phenotype of CD. 
For the analysis of quantitative immunological re-
sponse, the Cochran-Armitage test was used to deter-
mine whether there was a linear trend between the 
ordered categories of antibody response defined by 
quartiles and the proportion of patients with a specific 
disease. Results were expressed as odds ratios (Odds) 
Table I. Characteristics and clinical phenotypes of the inflammatory bowel disease cohort
Variables Crohn’s disease patients 
 (N = 109)
Ulcerative colitis patients 
(N = 25)
Male/female, n (%) 64/45 (58.7) 8/17 (32.0) 
Median age at diagnosis (IQR) [years] 11.2 (7.4–15.2) 12.8 (10.4–15.3)
Mean age of symptoms onset (± SD) [years] 10.0 ±4.8 11.8 ±3.5
Mean time of symptoms duration before diagnosis (± SD) [months] 12.4 ±18.9 3.05 ±4.1*
CD age (A) at diagnosis, n (%):
  A1a (< 10 years)
  A1b (10–17 years)
  A2 (17–40 years) 
46 (42.2) 
47 (43.1)
16 (14.7)
–
–
–
CD location (L), n (%):
  L1 (ileal)
  L2 (colonic)
  L3 (ileocolonic)
  L4
a
 + L4
b
 (upper GI proximal to 1/3 distal ileum)
 8 (7.3)
41 (37.6)
60 (55.0)
53 (48.6)
–
–
–
–
CD behaviour (B), n (%):
  B1 (inflammatory)
  B2 (stricturing)
  B3 (penetrating)
  p (perianal disease)
91 (83.5)
15 (13.7)
3 (2.8) 
28 (25.7) 
–
–
–
–
CD growth retardation (G), n (%):
  G0 (no evidence)
  G1 (growth delay)
78 (71.6)
31 (28.4) 
–
–
UC extension (E), n (%):
  E1 (proctitis)
  E2 (distal to splenic flexure)
  E3 (distal to hepatic flexure)
  E4 (proximal to hepatic flexure)
–
–
–
–
1 (4.0) 
2 (8.0) 
3 (12.0) 
19 (76.0) 
UC severity (S), n (%):
  S0 (never sever; PUCAI < 65)
  S1 (ever severe; PUCAI ≥ 65)
–
–
17 (68.0) 
8 (32.0) 
CD – Crohn’s disease, UC – ulcerative colitis, SD – standard deviation, IQR – interquartile range, PUCAI – Paediatric Ulcerative Colitis Activity Index, *p < 0.001
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and 95% confidence intervals (CIs). Statistical signifi-
cance was defined as a two-tailed p-value < 0.05.
Results
Presence and profile of anti-glycan 
antibodies in Crohn’s disease patients
A significant proportion of CD patients responded to 
glycan antigens. The prevalence of ASCA, ACCA, ALCA, 
and AMCA in CD and UC patients as well as the controls 
is presented in Table II. ASCA were positive in 59.6% of 
CD patients and in 10.5% of the controls (OR = 12.38, 
95% CI: 5.19–29.57, p < 0.001). There was no difference 
in the prevalence of ASCA in UC compared to the con-
trol group (OR = 0.745, 95% CI: 0.144–3.857, p = 0.726), 
but it was significantly lower as compared to CD pa-
tients (OR = 0.001, 95% CI: 0.0003–0.006, p < 0.001). 
Among the new anti-glycan antibodies, ALCA were sig-
nificantly more prevalent in CD than in UC (OR = 14.614, 
95% CI: 2.858–240.979, p < 0.007) or in the controls 
(OR = 9.176, 95% CI: 2.092–40.254, p < 0.001). For ACCA, 
the values approximated significance for the controls 
(OR = 2.078, 95% CI: 0.987–4.375, p = 0.055) but were 
not different in comparison to UC patients (OR = 2.380, 
95% CI: 0.783–7.470, p = 0.137). 
The presence of antibodies directed to one of the 
glycan epitopes (ASCA, ACCA, ALCA, or AMCA) was 
significantly associated with CD (Table II). At least 
one positive antibody of the panel was more prev-
alent in CD patients compared both to UC subjects 
(OR = 9.617, 95% CI: 3.482–26.562, p < 0.001) and 
the controls (OR = 7.137, 95% CI: 3.614–14.095, 
p = 0.001). Seventy-five percent of CD patients were 
positive for one of the anti-glycan antibodies, while 
76% of UC patients and 70% of the controls did not 
show any antibodies. A higher level of the immune re-
sponse as expressed by the number of positive anti-gly-
can antibodies was significantly associated with CD 
(p = 0.0097); however, a limited overlap of antibodies 
was observed. The sera of 33.9% of CD patients reacted 
with two glycan epitopes, while 11.9% of CD subjects 
were positive for three antigens and only 1 patient ex-
pressed all four anti-glycan antibodies (Table II). Test-
ing for ACCA, ALCA, and AMCA allowed for serological 
identification of an additional subgroup of CD patients, 
who did not express immunoreactivity toward mannan 
epitopes of Saccharomyces cerevisiae. Among 45 AS-
CA-negative CD patients, serological response to one of 
the new glycan epitopes was found in almost half (49%) 
of them, including ACCA present in 31%, ALCA in 13%, 
and AMCA in 4% of the subjects.
Diagnostic accuracy and use 
for diagnosis and differentiation 
Based on the manufacturer-recommended cut-off 
values the sensitivity and specificity, positive and neg-
ative predictive values of the serological markers were 
calculated for clinical situations differentiating CD from 
the controls and distinguishing CD from UC. Table III 
shows the results for each of the individual markers. 
All of the anti-glycan antibodies were highly specific 
(80–100%) for CD, with the highest values characteris-
ing ALCA (97–100%). ASCA presented the highest sen-
sitivity for differentiation of CD from both the controls 
(59%) and UC (59%). The sensitivity of the other an-
Table II. Anti-glycan antibodies distribution in the studied groups
Factor Crohn’s disease patients  
(N = 109)
Ulcerative colitis patients  
(N = 25)
Controls  
(N = 67)
Median (IQR) levels, EU:
  ACCA
  ALCA
  AMCA
37.7 (21.5–54.7)
25.8 (18.4–57.0)
42.8 (31.33–60.2)
33.2 (24.7–40.3)
24.0 (19.1–30.7)
37.4 (30.1–54.9)
30.9 (23.3–46.1)
25.4 (18.8–34.1)
39.1 (29.2–59.1)
Antibody positivity, n (%)
  ASCA*,**
  ACCA (≥ 90 EU)
  ALCA (≥ 60 EU)*,**
  AMCA (≥ 100 EU)
65 (59.6)
34 (31.1)
24 (22)
11 (10.1)
2 (8)
4 (16)
0 (0)
2 (8)
7 (10.5)
12 (17.9)
2 (2.9)
4 (5.9)
Number of positive AGABs, n (%)*,**
  1
  2
  3
  4
82 (75.2) 
37 (33.9) 
13 (11.9)
1 (1)
6 (24) 
2 (8)
0 (0)
0 (0)
20 (29.9)
5 (7.5)
0 (0)
0 (0)
CD – Crohn’s disease, UC – ulcerative colitis, ACCA – anti-chitobioside carbohydrate antibody, ALCA – anti-laminaribioside carbohydrate antibody,  
AMCA – anti-mannobioside carbohydrate antibody, ASCA – anti-Saccharomyces cerevisiae antibody, AGABs – anti-glycan antibodies (positive ASCA, ACCA, 
ALCA, or AMCA), IQR – interquartile range, EU – ELISA units, *p < 0.05 CD vs. controls, **p < 0.05 CD vs. UC
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ti-glycan antibodies was low and had values from 10% 
to 33% (Table III). The best performance for positive 
predictive values was shown by ALCA (92–100%) and 
ASCA (90–97%). For clinical situations, when negative 
predictive values are of importance to avoid invasive 
diagnostic procedures, all the new anti-glycan antibod-
ies presented poor levels that ranged from 19% to 50%, 
as shown in Table III. 
To differentiate CD from the controls and UC in-
dependently of the cut-off levels, we constructed ROC 
curves for ACCA, ALCA, and AMCA. All the anti-glycan 
antibodies showed a weak discriminatory capaci-
ty for differentiation of CD from UC (AUC
ACCA
 – 0.554, 
95% CI: 0.445–0.664; AUC
ALCA
 – 0.611, 95% CI: 0.506–
0.716; AUC
AMCA
 – 0.568, 95% CI: 0.443–0.693) and the 
controls (AUC
ACCA
 – 0.5596, 95% CI: 0.474–0.645; AUC
ALCA 
– 0.572, 95% CI: 0.488–0.656, AUC
AMCA
 – 0.553, 95% CI: 
0.464–0.642). The only significant difference in anti-
bodies level was found for ALCA, which presented high-
er values in the older (10 to 17 years) age group (46.3 
±31.54 vs. 31.9 ±24.25 EU, p = 0.012).
Serological response association 
with disease phenotype
In the univariate analysis, no association was found 
between the prevalence of each individual marker and 
disease phenotype, including age at diagnosis, disease 
behaviour, and disease location (p > 0.05). To determine 
which antibody was independently associated with spe-
cific disease characteristics, multivariate logistic regres-
sion analysis was performed. Taking into account sepa-
rately age at diagnosis, disease localisation, and disease 
behaviour as potential confounders, we found an inde-
pendent association between one of the newer anti-gly-
can antibodies (ACCA, ALCA, AMCA) and ileocolonic 
disease location (L3; OR = 4.444, 95% CI: 1.670–11.830, 
p = 0.0147). Among antibodies, only ALCA was signifi-
cantly more likely to be linked with this disease location 
(OR = 4.429, 95% CI: 0.5733–34.211, p = 0.018). Isolated 
ileal disease was omitted from this analysis because 
of the low number of patients with this location. The 
multivariate logistic regression model revealed that the 
presence of one antibody of the entire anti-glycan panel 
(ASCA, ACCA, ALCA, AMCA) was associated with compli-
cated disease behaviour (B2, B3) (p = 0.043).
To evaluate a possible association between the level 
of antibody response to the new anti-glycan antigens 
and CD phenotype, the quartile scores analysis individ-
ually for ACCA, ALCA, and AMCA (Table IV) and cumu-
lative quartile scores of the sum (Figure 1) for all the 
antibodies were calculated as stated in the Material and 
methods section. We found that an increasing cumula-
tive response to glycans was associated with older age 
at diagnosis (p = 0.0467) and a decreasing likelihood for 
disease localisation limited to the colon (p = 0.0295). 
For individual antibodies, an increasing response asso-
ciated with older age at diagnosis was significant for 
ALCA (p = 0.017), and decreasing disease localisation in 
the colon was significant for ACCA (p = 0.0014). There 
was no trend among the quartile scores for any of the 
individual antibodies or for the quartile sum scores and 
disease behaviour (p > 0.05). 
Discussion
In the present study of a well-defined paediatric IBD 
cohort, we evaluated a potential association between 
Table III. Diagnostic accuracy of each studied marker for differentiation of CD (n = 109) with the controls (n = 67) 
and UC (n = 25)
Sensitivity 
[%]
95% CI [%] Specificity 
[%]
95% CI [%] PPV 95% CI [%] NPV [%] 95% CI [%]
CD vs. controls: 
ASCA 59 49–68 90 80–96 90 81–96 57 47–67
ACCA (≥ 90 EU) 31 23–41 82 71–90 74 59–86 42 34–51
ALCA (≥ 60 EU) 27 18–37 97 90–99 92 75–99 50 41–59
AMCA (≥ 100 EU) 10 5–17 92 74–99 85 55–98 19 12–27
CD vs. UC:
ASCA 59 49–68 92 74–99 97 90–99 34 23–46
ACCA (≥ 90 EU) 33 24–43 80 59–93 88 74–96 22 14–31
ALCA (≥ 60 EU) 22 15–31 100 86–100 100 86–100 23 15–32
AMCA (≥ 100 EU) 10 5–17 92 74–99 85 55–98 19 12–27
CD – Crohn’s disease, UC – ulcerative colitis, ACCA – anti-chitobioside carbohydrate antibody, ALCA – anti-laminaribioside carbohydrate antibody, AMCA – 
anti-mannobioside carbohydrate antibody, ASCA – anti-Saccharomyces cerevisiae antibody, PPV – positive predictive value, NPV – negative predictive value, 
CI – confidence interval, EU – ELISA unit
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Table IV. Quartile analysis of the Crohn’s disease cohort (n = 109) for the three markers (ACCA, ALCA, and AMCA) 
for age at diagnosis (A), disease behavior (B), and disease location (L)
Markers Q1 Q2 Q3 Q4 Value of p
ACCA A1a 15 (33%) 13 (28%) 7 (15%) 11 (24%) 0.15
A1b 9 (19%) 11 (23%) 15 (32%) 12 (26%)
ALCA A1a 16 (35%) 14 (30%) 9 (20%) 7 (15%) 0.017
A1b 9 (19%) 10 (21%) 14 (30%) 14 (30%)
AMCA A1a 16 (35%) 9 (20%) 11 (24%) 10 (22%) 0.380
A1b 11 (23%) 11 (23%) 14 (30%) 11 (23%)
ACCA B1 24 (26%) 19 (21%) 24 (26%) 24 (26%) 0.388
B2 + B3 4 (22%) 8 (44%) 3 (17%) 3 (17%)
ALCA B1 25 (27%) 23 (25%) 21 (23%) 22 (24%) 0.329
B2 + B3 3 (17%) 4 (22%) 6 (33%) 5 (28%)
AMCA B1 24 (26%) 21 (23%) 23 (25%) 23 (25%) 0.863
B2 + B3 4 (22%) 6 (33%) 4 (22%) 4 (22%)
ACCA L1 3 (43%) 3 (43%) 0 (0%) 1 (14%)
L2 14 (34%) 9 (22%) 11 (27%) 7 (17%) 0.001
L3 11 (18%) 15 (25%) 15 (25%) 19 (32%)
ALCA L1 2 (29%) 4 (57%) 0 (0%) 1 (14%)
L2 12 (29%) 9 (22%) 13 (32%) 7 (17%) 0.119
L3 13 (22%) 14 (23%) 14 (23%) 19 (32%)
AMCA L1 3 (43%) 2 (29%) 0 (0%) 2 (29%)
L2 13 (32%) 11 (27%) 8 (20%) 9 (22%) 0.117
L3 12 (20%) 14 (23%) 18 (30%) 16 (27%)
CD – Crohn’s disease, Q – quartile, ACCA – anti-chitobioside carbohydrate antibody, ALCA – anti-laminaribioside carbohydrate antibody,  
AMCA – anti-mannobioside carbohydrate antibody, ASCA – anti-Saccharomyces cerevisiae antibody, A1a – age of diagnosis < 10 years, A1b – age of diagnosis 
10–17 years, B1 – inflammatory disease, B2 – stricturing disease, B3 – penetrating disease, L1 – ileal disease, L2 – colonic disease, L3 – ileocolonic disease
an adaptive response to the panel of glycan epitopes, 
including ASCA, ACCA, ALCA, and AMCA, and the clin-
ical presentation of CD. Moreover, we tested whether 
the new markers (ACCA, ALCA, and AMCA) could be 
helpful in disease differentiation and stratification. We 
confirmed the association between some anti-glycan 
antibodies (ACCA, ALCA) and CD, detecting a correlation 
between the presence of antibodies and complicated 
disease presentation and ileocolonic disease location. In 
addition, a higher level of adaptive response was associ-
ated with older age at diagnosis and ileocolonic disease. 
Although newer anti-glycan antibodies were highly spe-
cific for CD, their capability as a screening tool for diag-
nosis of primary CD was limited, and ASCA antibodies re-
main the most accurate single marker for paediatric CD. 
Profile of anti-glycan antibodies 
and association with disease phenotype
In this study, qualitative and quantitative immune 
response to glycan epitopes was strongly associated 
with CD and specific disease phenotype. Notably, the 
serological response to glycans was complex, and de-
spite a relatively high frequency of antibodies present in 
CD patients, a limited overlap was found. The observed 
wide variation in both the number and magnitude of 
immune responses as expressed by the quartile sum 
scores to glycans indicates that the degree of reactivity 
to microbial components is not uniform in all paediat-
ric CD patients. Testing for the new set of antibodies, 
which allowed for serological identification of an addi-
tional subgroup of CD patients, may facilitate the dis-
crimination of indeterminate IBD-phenotype. Forty-nine 
percent of those who did not show immune reactivity 
toward mannan epitopes of Saccharomyces cerevisiae 
were positive for at least one other marker from the 
panel. A similar distribution of anti-glycan antibodies 
with respect to the status of the markers as well as 
diversification of the response to anti-glycan epitopes 
have been published in studies performed in adults [17, 
19, 21, 22]. Rieder et al. reported 40.9% ASCA-negative 
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Figure 1. Cumulative quartile sum analysis of 
the Crohn’s disease cohort for the three tested 
anti-glycan antibodies (ACCA, ALCA, and AMCA). 
The distribution of quartile sum scores in rela-
tion to age at diagnosis (p = 0.47) (A), disease 
localisation (p = 0.047) (B) and disease behavior 
(p = 0.94) (C)
CD – Crohn’s disease, SSQ – quartile sum scores (after aggregation 
by two), ACCA – anti-chitobioside carbohydrate antibody, ALCA 
– anti-laminaribioside carbohydrate antibody, AMCA – anti-
mannobioside carbohydrate antibody, ASCA – anti-Saccharomyces 
cerevisiae antibody, A1a – age of diagnosis < 10 years, A1b – 
age of diagnosis 10–17 years, L1 – ileal localisation, L2 – colonic 
localisation, L3 – ileocolonic localisation, B1 – inflammatory disease, 
B2 – stricturing form, B3 – penetrating form
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CD children to be positive for at least one other marker 
from the anti-glycan panel [20]. This illustrates the im-
portance of combined testing of newer glycan antibod-
ies in a specific group of patients, and their potential 
usefulness as an additional tool in cases of diagnostic 
uncertainty. 
There is a growing body of evidence indicating that 
the pathogenesis of CD is strongly associated with ab-
errant recognition of resident intestinal microbial com-
ponents [1]. Glycans are cell wall surface carbohydrate 
components that can be found on various pathogenic 
and saprophytic microorganisms playing a role in di-
versified immunological processes and stimulating im-
mune response in a Syk-dependent way [19, 23]. The 
non-uniform nature of the serological response to gly-
can epitopes may reflect different levels of the altered 
host-microbial relationship and might be related to 
diverse immunological mechanisms (e.g. antigen sam-
pling, antigen recognition, antigen clearance) affected 
by genetic heterogeneity and/or varied microbiome 
components [1]. Therefore, specific antibodies may be 
the sign of an underlying pathomechanism associated 
with a characteristic disease presentation. The inflam-
matory behaviour is dominantly diagnosed in CD pa-
tients at disease onset, but the disease phenotype is 
not stable and progression to a complicated form can 
evolve in most patients during years of disease dura-
tion [3, 4]. After initial observations concerning ASCA, 
several other serologicalal markers have been linked 
with more complicated disease presentation and se-
vere disease course [15]. Studies in adults indicate 
that patients with complicated CD disease were more 
likely to show the presence of anti-glycan antibodies; 
however, an inconsistent association between individ-
ual anti-glycan antibodies and disease phenotype has 
been reported [17–22, 24–29]. We confirmed that in 
paediatric patients, anti-glycan antibodies were asso-
ciated with a complicated disease already at disease 
onset. Because it was a single time point study with 
no follow-up, we cannot draw a conclusion addressing 
a predictive association with the disease course. The 
only paediatric study to date suggests an association 
between anti-glycan antibodies and complicated dis-
ease phenotype, and a predictive role of the more se-
vere course of the disease [20]. Once the diagnosis of 
CD is established, anti-glycan antibodies might be an 
important serologicalal marker for disease stratification 
and could be considered as an additional tool to identify 
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high-risk patients. This may have a significant clinical 
implication because the introduction of a more potent 
therapeutic regimen (e.g. biologic and/or immunomod-
ulators) early in the disease course may be of benefit in 
patients with a higher risk of complicated CD. 
In agreement with studies in adults, we found that 
the magnitude of the immune response to glycans was 
associated with a more extensive disease localisation, 
involving the colon and terminal ileum [22, 25]. How-
ever, unlike Rieder et al., we were not able to show an 
association between anti-glycan antibodies and ileal 
CD [20]. It could be partially explained by the much 
lower proportion of patients with limited ileal localisa-
tion, which in our cohort was present in only 8 (7.3%) 
subjects (Table I). Paediatric CD is characterised by 
a large proportion of colonic involvement, ileitis is usu-
ally associated with colitis (55% of the patients in our 
cohort), and the cumulative probability of isolated ileal 
CD increases with age until puberty [30]. Differences in 
disease classification, since we applied the Paris classifi-
cation and time of blood procurement in relation to the 
stage of disease duration, may influence the results and 
limit the possibility of comparing these two studies [8].
 
Anti-glycan antibodies diagnostic
accuracy 
The diagnostic differentiation between CD and UC 
has both therapeutic and prognostic implications. In 
the majority of IBD patients it can be made based on 
clinical, endoscopic, histopathological, and radiologi-
cal features. However, in a subgroup of patients with 
strictly colonic disease, differentiation may be a chal-
lenge and serological tests could be supportive. As in 
previous studies, our results indicate that the new an-
ti-glycan antibodies are specific for CD [9, 19]. However, 
no antibody demonstrated a sufficient sensitivity to 
support their usefulness as a screening tool for primary 
paediatric CD in the diagnostic workup algorithm. The 
diagnostic accuracy of the ASCA and ALCA for differen-
tiation of CD versus UC has been reported to be similar 
between adults and children, while some discrepancies 
have been found for AMCA and ACCA [25, 26, 31]. As in 
the case of our data, most studies indicate that among 
the new anti-glycan antibodies, AMCA gives poor values 
for both sensitivity and specificity [9]. When analysing 
the differentiation capability of the markers, the new 
anti-glycan antibodies taken individually have not im-
proved differentiation between CD and UC and the con-
trols. ASCA may still be considered the most accurate 
single marker from the anti-glycan panel. 
Analysis of the diagnostic accuracy of newer an-
ti-glycan antibodies, independently of the recommend-
ed cut off values, showed no differences of titre levels 
between the studied groups. Moreover, the ROC curves 
have shown a weak discriminatory capability. Data 
from adult studies are inconsistent in terms of titres 
for individual markers, as well as a possible associa-
tion between the serological response and age at the 
disease onset [20–22, 25, 26]. The only paediatric study 
indicates that the cut-off values for the new anti-glycan 
antibodies are lower than those for adults [20]. In our 
study, an increasing magnitude of the immune response 
to glycans has been associated with older age at diag-
nosis, which could be explained by a dependency in an-
tibody production on the age at diagnosis, as previously 
described [32]. Therefore, the age-dependent differenc-
es in serological response should be taken into account 
and different cut-off values for optimal performance of 
the anti-glycan antibodies may apply as dependent on 
age. Further studies on larger patient populations to 
establish paediatric referral cut-off values are definitely 
needed. 
This study is not without limitations. The first possi-
ble limitation is due to a tertiary centre referral bias and 
higher pre-test probability compared to the general pop-
ulation, due to the diagnosis of CD and UC already hav-
ing been established at the time of sample procurement. 
The second limitation is the cross-sectional study design 
with single point antibody measurements and no lon-
gitudinal observation. Therefore, results in the conclu-
sion regarding the prognostic values of the anti-glycan 
antibodies from this study should be formulated with 
caution. On the other hand, ASCA appears even years 
before CD diagnosis, and until now a predominant num-
bers of studies in adult patients have reported antibody 
responses to be stable over time, despite different ther-
apeutic modalities being employed, including active and 
inactive disease [33–35]. As mentioned above, distinct 
cut-off values for the paediatric CD population, for the 
optimal performance of the markers, have to be taken 
into account although the optimal cut-off values for the 
glycan marker panel have not been determined to date.
Conclusions
Our results suggest that some new anti-glycan an-
tibodies are associated with paediatric CD and specific 
disease phenotype, and may be supportive in stratifying 
disease subtypes. With the growing evidence of an as-
sociation between serological response and a compli-
cated and more extended disease phenotype, the most 
important clinical value of anti-glycan antibodies could 
be in the stratification of patients according to the risk 
of presentation a more severe disease. Therefore, fur-
ther studies are definitely needed to evaluate the said 
risk. The diagnostic significance of individual new an-
ti-glycan antibodies to differentiate IBD from non-IBD 
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and CD from UC patients is of limited value and cannot 
replace conventional clinical evaluation. However, such 
tests may constitute an adjunctive tool in a specific 
group of patients, to aid in the differentiation of CD pa-
tients with absent ASCA from ulcerative colitis subjects. 
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